Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Tocilizumab
Tocilizumab
Routinely available
NICE (TA375 (SMC 593/09))
27/03/2024
Indication
Moderate to severe active rheumatoid arthritis
Therapeutic Area
Musculoskeletal and joint diseases
Status Description
Routinely available in line with local or regional guidance
Formulation
20mg/ml concentrate for solution for injection
Comments
NICE MTA advice: SMC advice 593/09 is superseded by NICE TA375. Refer to pathway or local board guidelines for preferred formulation.
Link to Advice
Advice Published
26/01/2016